With a move that redefines the boundaries of mental health, Eli Lilly has acquired AtaiBeckley for $3.8 billion, a pioneering company in psychedelic treatments counting among its early supporters the Trump-aligned billionaire and Palantir CEO Peter Thiel.
Amid a strategy of massive reinvestment of profits derived from obesity drugs, the world’s largest pharmaceutical company has decided to bet on innovative therapies still in early stages to address unmet clinical needs.
DETAILS OF THE ACQUISITION
The deal, reports the Financial Times, provides that Eli Lilly will pay $2.8 billion in cash, with an additional $1 billion contingent on achieving specific clinical development milestones. The set price, specifies Bloomberg, is $6.75 per share, representing a 26% premium over the market capitalization recorded at the close of the Wednesday prior to the announcement.
This operation is part of a broader expansion plan for Eli Lilly, which during 2026 announced biotech acquisition investments with a potential total value of $28.8 billion, including deals with Centessa Pharmaceuticals and Kelonia Therapeutics. The closing of the transaction with AtaiBeckley is expected in the third quarter of the year.
ATAIBECKLEY AND THE CONNECTION WITH PETER THIEL
AtaiBeckley was born last year from the merger between the British Beckley Psytech and Atai Life Sciences, a drug development platform founded by German entrepreneur Christian Angermayer.
The company has benefited since its inception from the prestige of high-profile investors, particularly Peter Thiel, co-founder of PayPal and Palantir, who led one of the company’s first private funding rounds.
Currently, writes the FT, Angermayer remains the main shareholder through his family office Apeiron Investment Group, holding a 14.5% stake. Commenting on the sector’s evolution, Angermayer emphasized how, if in 2014 the idea of a psychedelic comeback was considered crazy, today “psychedelic medicine seems almost inevitable.”
THERAPEUTIC PIPELINE AND CLINICAL CHALLENGES
The technological core of the acquisition lies in AtaiBeckley’s main candidate, called BPL-003, a nasal spray based on the hallucinogenic compound 5-MeO-DMT currently in Phase III trials for treatment-resistant depression. Carole Ho, executive vice president of Eli Lilly Neuroscience, stated that “millions of people are still seeking relief and are in desperate need of an effective cure” in light of the failure of conventional therapies.
In addition to this, the company is developing VLS-01, an oral compound based on DMT, and EMP-01, a variant of MDMA for social anxiety disorder. AtaiBeckley’s CEO, Srinivas Rao, explained that the goal is to create practical treatments that can easily integrate into existing clinical models, with the psychedelic experience duration reduced to about two hours.
DATA AND TRENDS IN THE PSYCHEDELIC MARKET
The global psychedelic drug market is experiencing accelerated growth, with an estimated valuation of $3.19 billion by 2025 and a projection reaching $12.89 billion by 2035, supported by a compound annual growth rate (CAGR) of 15%.
This dynamism is fueled by the urgent need to address the economic costs of mental health, which are expected to reach $5 trillion by 2030.
Geographically, the sector is dominated by North America, home to 71% of the more than 70 companies engaged in developing these therapies, followed by Europe with 23%. Ketamine currently holds the largest market share, while psilocybin shows the highest growth potential due to its effectiveness in treating addictions and mood disorders.
BETWEEN POLITICS AND ECONOMY
Interest in these substances has been further stimulated by political factors in the United States, such as the executive order signed by President Donald Trump to accelerate FDA approval procedures and the support of the Make America Healthy Again movement promoted by Health Secretary Robert F. Kennedy Jr.
Eli Lilly is not the only major multinational moving in this direction. Similar operations have been conducted by AbbVie, which acquired programs from Gilgamesh Pharmaceuticals, and by the Japanese company Otsuka. In this dynamic scenario, other sector companies such as Compass Pathways, MindMed, Cybin, and GH Research have seen significant increases in their stock prices, reflecting a climate of growing investor confidence in psychedelic medicine as the new frontier of psychiatry.
